Donate

News

 

Lymphoma Newsletter – January 2020

Lymphoma Newsletter & Update

In this month’s newsletter we are sharing:

  • 2020 Global Patient Survey
    link for your input. The Lymphoma Coalition survey is collecting  data from across the globe to help organisations such as ours to plan  support services and advocacy efforts, so that patients are receiving  the best available care and support, when needed. If you can, please  take the time to complete this survey.
  • The next PBAC meeting
    in March will be considering three new treatments for two lymphoma subtypes.     Submissions are now open
  • In December, Lymphoma Australia attended the American Society of Hematology Meeting
    and now have more than 40 interviews with leading lymphoma experts
    available to watch. A very big thank you to AbbVie for your support and
    giving us the opportunity to bring this information to patients across
    the world. 
  • Legs Out for Lymphoma awareness walks will be on again this year! Save the dates to join us in raising awareness, putting lymphoma in the limelight and “legs get together”!

Read more… 

Wishing you a very healthy 2020.

Sharon Winton, CEO

Share This
Cart
Checkout - $0.00
  • 0
  • 1

Contact Lymphoma Australia Today!

Patient Support Hotline

General Enquiries

Please note: Lymphoma Australia staff are only able to reply to emails sent in English language.

For people living in Australia, we can offer a phone translation service. Have your nurse or English speaking relative call us to arrange this.

Useful Definitions

  • Refractory: This means the lymphoma does not get better with treatment. The treatment didn’t work as hoped.
  • Relapsed: This means the lymphoma came back after being gone for a while after treatment.
  • 2nd line treatment: This is the second treatment you get if the first one didn’t work (refractory) or if the lymphoma comes back (relapse).
  • 3rd line treatment: This is the third treatment you get if the second one didn’t work or the lymphoma comes back again.
  • Approved: Available in Australia and listed by the Therapeutics Goods Administration (TGA).
  • Funded: Costs are covered for Australian citizens. This means if you have a Medicare card, you shouldn’t have to pay for the treatment.[WO7]

You need healthy T-cells to make CAR T-cells. For this reason, CAR T-cell therapy cannot be used if you have a T-cell lymphoma – yet.

For more information on CAR T-cells and T-cell lymphoma click here. 

Special Note: Although your T-cells are removed from your blood for CAR T-cell therapy, most of our T-cells live outside of our blood – in our lymph nodes, thymus, spleen and other organs.